2 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
Follow T-MAXIMUM Pharmaceutical Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 - Brain Metastases From Solid Tumors | Phase 2 | Not yet recruiting | T-MAXIMUM Pharmaceutical Inc | 40 | 2027-12-30 | 2026-10-27 |
| The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3 - Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 2 | Not yet recruiting | T-MAXIMUM Pharmaceutical Inc | 40 | 2026-11-30 | 2026-10-14 |
Recurrence (1)
Taiwan (2) · United States (2)